SEHK:1093Pharmaceuticals
What CSPC Pharmaceutical Group (SEHK:1093)'s US$4.7 Billion AstraZeneca Metabolic Deal Means For Shareholders
AstraZeneca recently announced a new collaboration with CSPC Pharmaceutical Group to advance eight next-generation obesity and type 2 diabetes therapies, anchored by CSPC’s AI-driven peptide discovery and once-monthly LiquidGel injection platform, with AstraZeneca receiving worldwide rights outside China to CSPC’s once-monthly injectable weight management portfolio.
The agreement includes an upfront payment of US$1.20 billion and up to US$3.50 billion in potential development and regulatory...